Drug intelligence / Profile preview

ITGA-2 neutralizing antibody

Development stage: Preclinical
Lead developer: Boston Children's Hospital
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ITGA-2 neutralizing antibody is a therapeutic monoclonal antibody designed to target and inhibit integrin alpha-2 (ITGA-2), a cell surface marker found to be highly overexpressed in glioblastoma multiforme (GBM) and other high-grade gliomas compared to healthy brain tissue. Developed by researchers at Children's Hospital Boston, the antibody acts by blocking ITGA-2, which has been shown in preclinical studies to significantly reduce the growth and migration of GBM tumor cells. The target ITGA-2 demonstrates higher specificity and expression levels in GBM compared to the established target EGFR, suggesting potential as a more effective therapeutic or diagnostic marker.

Other names: anti-ITGA-2 antibodyanti-ITGA2 antibodyanti-ITGA 2 antibodyintegrin alpha-2 neutralizing antibody

Targets

ITGA2 (Integrin alpha-2)

Beyond the preview

Go deeper on ITGA-2 neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITGA-2 neutralizing antibody.

Explore the full profile